Aβ-related memory decline in APOE ϵ4 noncarriers: Implications for Alzheimer disease

Neurology

Volumn 86, Issue 17, 2016, Pages 1635-1642

  Lim, Yen Ying ^a   Laws, Simon M ^b,h,i   Villemagne, Victor L ^a,g   Pietrzak, Robert H ^c   Porter, Tenielle ^b,h,i   Ames, David ^a,d   Fowler, Christopher ^a   Rainey Smith, Stephanie ^b   Snyder, Peter J ^e   Martins, Ralph N ^b   Salvado, Olivier ^f   Bourgeat, Pierrick ^f   Rowe, Christopher C ^g   Masters, Colin L ^a   Maruff, Paul ^a,j  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^e BROWN UNIVERSITY   (United States)

^f CSIRO   (Australia)

^g AUSTIN HEALTH   (Australia)

^h HOLLYWOOD PRIVATE HOSPITAL   (Australia)

ⁱ School of Earth and Environmental Sciences   (Australia)

^j CogState Ltd ^*  (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMAN; LANGUAGE; LANGUAGE DISABILITY; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ALZHEIMER DISEASE; BRAIN; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; GENETICS; HETEROZYGOTE; METABOLISM; NEUROPSYCHOLOGICAL TEST; PRODROMAL SYMPTOM; PSYCHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; HETEROZYGOTE; HUMANS; MALE; MEMORY DISORDERS; MEMORY, EPISODIC; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS;

EID: 84964861819     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002604     Document Type: Article

References (30)

1. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle study of ageing. Ann Neurol 2013;74:905-913.
2. Jack CR, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347-1358.
3. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.
4. Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE E4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 2014;82: 1760-1767.
5. Lim YY, Villemagne VL, Laws SM, et al. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry 2015;20:1322-1328.
6. Lim YY, Villemagne VL, Pietrzak RH, et al. APOE e4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 2015;36: 1239-1244.
7. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106-118.
8. Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron 2014; 81:740-754.
9. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009;21:672-687.
10. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
11. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med 2004;256:240-246.
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
13. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
14. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913-920.
15. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-329.
16. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. J Am Med Assoc 2011;305:275-283.
17. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014; 137:221-231.
18. Harrington K, Lim YY, Ellis KA, et al. The effect of Aβ amyloid and APOE e4 on composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr 2013;25: 1667-1677.
19. Raber J, Wong D, Yu GQ, et al. Apolipoprotein E and cognitive performance. Nature 2000;404:352-354.
20. Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM. Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration. J Alzheimers Dis 2010;22:959-970.
21. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303.
22. Dumanis SB, Tesoriero JA, Babus LW, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 2009;29:15317-15322.
23. Hudry E, Dashkoff J, Roe AD, et al. Gene transfer of human Apoe isoform results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013;5:212ra161.
24. Tamamizu-Kato S, Cohen JK, Drake CB, Kosaraju MG, Drury J, Narayanaswami V. Interaction with amyloid beta peptide compromise the lipid binding function of apolipoprotein E. Biochemistry 2008;47:5225-5234.
25. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
26. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE e4 effect. N Engl J Med 2009;361:255-263.
27. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's disease neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201-209.
28. Dagley A, LaPoint M, Huijbers W, et al. Harvard Aging Brain Study: dataset and accessibility. NeuroImage 2015; pii: S1053-8119(15)002657.
29. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69.
30. Jack CR, Wiste HJ, Lesnick TG, et al. Brain β-amyloid load approaches a plateau. Neurology 2013;80:1-7.